Therefore, a combination of IDO inhibitors and treatment of ICIs has been proposed to enforce TILs and their functional capabilities in TME and thus eradicate either IDO-expressing or nonexpressing poorly immunogenic cancer cells [184]. Here, IDO1 is linked to cancer.